Michael Detmar

Dr. Michael Detmar

ETH Zurich
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
QMQiaoli Ma
Qiaoli Ma
BIBenjamin V. Ineichen
Benjamin V. Ineichen
MDMichael Detmar
Michael Detmar
SPSteven T. Proulx
Steven T. Proulx
Cerebrospinal fluid (CSF) has been commonly accepted to drain through arachnoid projections from the subarachnoid space to the dural venous sinuses. However, a lymphatic component to CSF outflow has long been known. Here, we utilize lymphatic-reporter mice and high-resolution stereomicroscopy to characterize the anatomical routes and dynamics of outflow of CSF. After infusion into a lateral ventricle, tracers spread into the paravascular spaces of the pia mater and cortex of the brain. Tracers also rapidly reach lymph nodes using perineural routes through foramina in the skull. Using noninvasive imaging techniques that can quantify the transport of tracers to the blood and lymph nodes, we find that lymphatic vessels are the major outflow pathway for both large and small molecular tracers in mice. A significant decline in CSF lymphatic outflow is found in aged compared to young mice, suggesting that the lymphatic system may represent a target for age-associated neurological conditions.

4 April 2005 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SHSatoshi Hirakawa
Satoshi Hirakawa
SKShohta Kodama
Shohta Kodama
RKRainer Kunstfeld
Rainer Kunstfeld
KKKentaro Kajiya
Kentaro Kajiya
LBLawrence F. Brown
Lawrence F. Brown
MDMichael Detmar
Michael Detmar
The mechanisms of tumor metastasis to the sentinel lymph nodes are poorly understood. Vascular endothelial growth factor (VEGF)-A plays a principle role in tumor progression and angiogenesis; however, its role in tumor-associated lymphangiogenesis and lymphatic metastasis has remained unclear. We created transgenic mice that overexpress VEGF-A and green fluorescent protein specifically in the skin, and subjected them to a standard chemically-induced skin carcinogenesis regimen. We found that VEGF-A not only strongly promotes multistep skin carcinogenesis, but also induces active proliferation of VEGF receptor-2–expressing tumor-associated lymphatic vessels as well as tumor metastasis to the sentinel and distant lymph nodes. The lymphangiogenic activity of VEGF-A–expressing tumor cells was maintained within metastasis-containing lymph nodes. The most surprising finding of our study was that even before metastasizing, VEGF-A–overexpressing primary tumors induced sentinel lymph node lymphangiogenesis. This suggests that primary tumors might begin preparing their future metastatic site by producing lymphangiogenic factors that mediate their efficient transport to sentinel lymph nodes. This newly identified mechanism of inducing lymph node lymphangiogenesis likely contributes to tumor metastasis, and therefore, represents a new therapeutic target for advanced cancer and/or for the prevention of metastasis.

21 August 2017 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
TCThe FANTOM Consortium
The FANTOM Consortium
DRDerek de Rie
Derek de Rie
IAImad Abugessaisa
Imad Abugessaisa
Tanvir AlamTanvir Alam
Tanvir Alam
EAErik Arner
Erik Arner
MHMichiel J L de Hoon
Michiel J L de Hoon

3 March 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
Sinem KaramanSinem Karaman
Sinem Karaman
MDMichael Detmar
Michael Detmar
Malignant tumors release growth factors such as VEGF-C to induce lymphatic vessel expansion (lymphangiogenesis) in primary tumors and in draining sentinel LNs, thereby promoting LN metastasis. Surprising recent evidence suggests that lymphatic vessels do not merely represent passive channels for tumor spread, but that they may actively promote tumor cell recruitment to LNs, cancer stem cell survival, and immune modulation. New imaging approaches allow the sensitive visualization of the earliest LN metastases and the quantitative, noninvasive measurement of the function of tumor-draining lymphatic vessels, with potential applications in the development of biomarkers for prognosis and measurement of therapeutic response.

1 March 2005 in The American Journal of Pathology
Verified
Journal Article
Closed access
VSVivien Schacht
Vivien Schacht
SDSoheil S. Dadras
Soheil S. Dadras
LJLouise Johnson
Louise Johnson
DJDavid G. Jackson
David G. Jackson
YHYoung-Kwon Hong
Young-Kwon Hong
MDMichael Detmar
Michael Detmar

10 October 2006 in Blood
Verified
Journal Article
Open access
PDF file
SHSatoshi Hirakawa
Satoshi Hirakawa
LBLawrence F. Brown
Lawrence F. Brown
SKShohta Kodama
Shohta Kodama
KPKarri Paavonen
Karri Paavonen
KAKari Alitalo
Kari Alitalo
MDMichael Detmar
Michael Detmar
The mechanisms by which tumors metastasize to sentinel and distant lymph nodes, and beyond, are poorly understood. We developed transgenic mice that overexpress vascular endothelial growth factor-C (VEGF-C) and green fluorescent protein specifically in the skin and studied the effects of chemically-induced skin carcinogenesis in this model. We found that in contrast to VEGF-A, VEGF-C does not increase the growth of primary tumors, but instead induces expansion of lymphatic networks within sentinel lymph nodes, even before the onset of metastasis. Once the metastatic cells arrived at the sentinel lymph nodes, the extent of lymphangiogenesis at these sites increased. Of importance, in mice with metastasis-containing sentinel lymph nodes, tumors that expressed VEGF-C were more likely to metastasize to additional organs, such as distal lymph nodes and lungs. No metastases were observed in distant organs in the absence of lymph node metastases. These findings indicate an important role of VEGF-C–induced lymph node lymphangiogenesis in the promotion of cancer metastasis beyond the sentinel lymph nodes. VEGF-C is therefore a good target to slow or even prevent the onset of metastasis.